ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

ProQR (Nasdaq: PRQR) announced management will present at the Citizens Life Sciences Conference on March 11, 2026 at 3:25pm ET.

Rhea-AI Summary

ProQR (Nasdaq: PRQR) announced management will present at the Citizens Life Sciences Conference on March 11, 2026 at 3:25pm ET. A live webcast and recording will be available via the company’s Investors & Media website events page. Archived webcasts will remain available for about 30 days.

Argus Mar 4 session

+13.33% close to close Open Argus

Details

News Market Reaction – PRQR

On Mar 4, the first trading day after this news, PRQR closed 13.33% above the previous close.

Data tracked by StockTitan Argus for the Mar 4 session.

Key Figures

Conference date: March 11, 2026 Presentation time: 3:25 pm ET Webcast archive period: 30 days +5 more

Conference date

March 11, 2026

Citizens Life Sciences Conference presentation

Presentation time

3:25 pm ET

Scheduled conference presentation slot

Webcast archive period

30 days

Duration webcast remains available after event

Collaboration milestones

$4.5M

2025 milestones from Eli Lilly reported Jan 2026

Cash balance

€106.9 million

Cash and equivalents at Sept 30, 2025

Net loss

€33.3 million

Nine‑month net loss to Sept 30, 2025, widened year over year

Planned Phase 1 size

33 participants

Planned AX-0810 Phase 1 trial enrollment

Ownership stake

14.6%

Van Herk group beneficial ownership as of Sept 30, 2025

Historical Context

5 past events · Latest: Feb 09

5 events

1. Feb 09

   Board changes

   24h Move

   -2.0%

   Planned rotation of two directors and search for new board members.

2. Jan 08

   Clinical and outlook

   24h Move

   -2.8%

   Encouraging AX-0810 Phase 1 safety/PK data and 2026 development outlook.

3. Dec 01

   Conference participation

   24h Move

   -9.4%

   Participation in Evercore healthcare conference and related investor outreach.

4. Nov 06

   Quarterly results

   24h Move

   -7.1%

   Q3 2025 financials with cash runway to mid-2027 and widened net loss.

5. Oct 20

   CTA authorization

   24h Move

   +9.7%

   CTA authorization for AX-0810 Phase 1 study and investor event announcement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

rna, adar-mediated

2 terms

rna medical

"transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing"

RNA (ribonucleic acid) is a natural molecule that carries instructions from a cell’s DNA to make proteins and can also act as a tool to turn genes on or off; think of it as a messenger or software that tells biological machinery what to build or modify. It matters to investors because RNA-based tests and therapies can create new markets or change treatment costs and regulatory risk, so progress or setbacks in RNA science often drive valuation swings in biotech companies.

adar-mediated medical

"transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing"

ADAR-mediated describes a natural cellular process where ADAR enzymes chemically change specific letters in RNA, effectively rewriting portions of a gene message before it becomes a protein. This matters to investors because such editing can alter disease pathways or treatment responses, so therapies, diagnostics, or drug candidates that target or rely on ADAR-mediated changes can materially affect a biotech company's value—think of it as tweaking a recipe that changes the final dish.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET.

A live webcast and recording of this presentation will be available from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date.

About Axiomer^™

ProQR is pioneering a next-generation RNA base editing technology called Axiomer^™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer^™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer^™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.

About ProQR

ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer^™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Learn more about ProQR at www.proqr.com.

ProQR Therapeutics N.V.

Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ProQR (PRQR) present at the Citizens Life Sciences Conference in 2026?

ProQR will present on March 11, 2026 at 3:25pm ET. According to ProQR, company management will deliver the presentation and a live webcast plus a recording will be available on the company Investors & Media events page for about 30 days.

How can investors watch the ProQR (PRQR) webcast from the March 11, 2026 presentation?

Investors can watch via the live webcast on ProQR’s Investors & Media events page. According to ProQR, the presentation will stream live and a recording will be posted under Events, with archived access for approximately 30 days after the presentation date.

Will a recording of ProQR's (PRQR) March 11, 2026 presentation be available after the webcast?

Yes. According to ProQR, a recording will be available on the company Investors & Media events page. The archived webcast will remain accessible for approximately 30 days following the March 11, 2026 presentation before it is removed from the events archive.

What topics will ProQR (PRQR) management cover at the March 11, 2026 Citizens Life Sciences Conference?

The announcement states management will present company developments but does not list topics. According to ProQR, the presentation will reflect recent company progress and outlook; viewers should consult the webcast for specific program details and management commentary.

Where on ProQR's website can I find the March 11, 2026 webcast and archived recording?

The webcast and recording will be posted in the Investors & Media > Events section of ProQR’s website. According to ProQR, the Events page will host the live stream and the archived webcast for roughly 30 days after the presentation.